Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AbbVie Humira Lawsuit Withstands Alvotech Attack

Attempt Fails To Dismiss Adalimumab Litigation Ahead Of FDA Decision On AVT02 Biosimilar

Executive Summary

Alvotech has failed in an attempt to dismiss US litigation initiated by AbbVie over Alvotech’s AVT02 proposed rival to higher-strength Humira. The company is expecting an FDA decision on the adalimumab biosimilar this month.

You may also be interested in...



Humira One Year Out: The Largest LOE Event In US Pharma History

Ahead of the first biosimilar Humira product set to launch in less than a year, In Vivo provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.

Humira One Year Out: The Largest LOE Event In US Pharma History

Ahead of the first biosimilar Humira product set to launch in 365 days, Generics Bulletin provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.

Alvo Group Opens London Offices

Following delays caused by the COVID pandemic, Róbert Wessman, founder and principal shareholder in the Alvo group of pharmaceutical companies, has formally opened the new London offices of his investment fund Aztiq at a ceremony in Hammersmith.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151211

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel